Published in Nat Commun on March 16, 2016
Protein Kinases C-Mediated Regulations of Drug Transporter Activity, Localization and Expression. Int J Mol Sci (2017) 0.75
Pharmacological characterization of a high-affinity p-tyramine transporter in rat brain synaptosomes. Sci Rep (2016) 0.75
Global transformation of erythrocyte properties via engagement of an SH2-like sequence in band 3. Proc Natl Acad Sci U S A (2016) 0.75
MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res (2004) 168.89
Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol (1993) 64.61
The fluid mosaic model of the structure of cell membranes. Science (1972) 37.43
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98
Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol (1999) 15.63
Statistical potential for assessment and prediction of protein structures. Protein Sci (2006) 8.98
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res (2011) 7.84
Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol (2004) 7.69
PROMALS3D: a tool for multiple protein sequence and structure alignments. Nucleic Acids Res (2008) 7.16
The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J (2000) 6.26
Subunit counting in membrane-bound proteins. Nat Methods (2007) 5.75
Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol (2011) 5.65
Mammalian ABC transporters in health and disease. Annu Rev Biochem (2001) 4.90
A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst (2000) 3.98
Probing cellular protein complexes using single-molecule pull-down. Nature (2011) 3.92
Structure and regulation of Src family kinases. Oncogene (2004) 3.44
The kamikaze approach to membrane transport. Nat Rev Mol Cell Biol (2001) 3.09
PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res (2014) 2.66
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 2.53
Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice. Genes Dev (1994) 2.28
Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev (2004) 2.18
Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet (1989) 2.15
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol (2002) 2.11
Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet (2005) 1.96
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther (2009) 1.94
Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2004) 1.82
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol (2010) 1.76
A secreted tyrosine kinase acts in the extracellular environment. Cell (2014) 1.74
Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol (2004) 1.73
Structure and dynamic regulation of Src-family kinases. Cell Mol Life Sci (2008) 1.69
Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics (2009) 1.62
Crystal structure of a eukaryotic phosphate transporter. Nature (2013) 1.60
Differential trafficking of Src, Lyn, Yes and Fyn is specified by the state of palmitoylation in the SH4 domain. J Cell Sci (2009) 1.49
Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res (2008) 1.46
Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol (1998) 1.44
What do drug transporters really do? Nat Rev Drug Discov (2014) 1.41
Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest (2010) 1.37
Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther (2011) 1.35
Structural basis for the drug extrusion mechanism by a MATE multidrug transporter. Nature (2013) 1.34
The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol Aspects Med (2013) 1.32
Nonreceptor tyrosine kinase c-Yes interacts with occludin during tight junction formation in canine kidney epithelial cells. Mol Biol Cell (2002) 1.32
Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem (1998) 1.31
Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol (2011) 1.31
Signaling from the living plasma membrane. Cell (2011) 1.29
Dasatinib. Nat Rev Drug Discov (2006) 1.25
Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain (2009) 1.24
Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol (2012) 1.23
Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res (2012) 1.15
Expression of cellular-yes protein in mammalian tissues. Oncogene (1990) 1.10
Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun (2004) 1.09
The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo. Mol Cell (1999) 1.09
Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A (2013) 1.08
Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther (2009) 1.06
Optimized atomic statistical potentials: assessment of protein interfaces and loops. Bioinformatics (2013) 0.99
Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer (2014) 0.99
Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. Clin Cancer Res (2013) 0.98
Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res (2014) 0.98
The genesis of tyrosine phosphorylation. Cold Spring Harb Perspect Biol (2014) 0.97
APP homodimers transduce an amyloid-β-mediated increase in release probability at excitatory synapses. Cell Rep (2014) 0.96
Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Mol Psychiatry (2011) 0.93
Cisplatin-induced renal injury is independently mediated by OCT2 and p53. Clin Cancer Res (2014) 0.90
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol (2015) 0.90
Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med (2012) 0.89
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorg Med Chem Lett (2013) 0.87
Stability of the human pregnane X receptor is regulated by E3 ligase UBR5 and serine/threonine kinase DYRK2. Biochem J (2014) 0.85
Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A (2015) 0.84
ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors. Pharm Res (2014) 0.82
Uptake carriers and oncology drug safety. Drug Metab Dispos (2013) 0.79
Regulation of organic cation transport in isolated mouse proximal tubules involves complex changes in protein trafficking and substrate affinity. Cell Physiol Biochem (2012) 0.79
Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res (2013) 1.24
Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A (2015) 0.84